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Prevention of inhalation anthrax requires early and extended antibiotic therapy, and therefore, alternative
treatment strategies are needed. We investigated whether a human monoclonal antibody (AVP-21D9) to
protective antigen (PA) would protect mice, guinea pigs, and rabbits against anthrax. Control animals
challenged with Bacillus anthracis Ames spores by the intranasal route died within 3 to 7 days. AVP-21D9 alone
provided minimal protection against anthrax in the murine model, but its efficacy was notably better in guinea
pigs. When Swiss-Webster mice, challenged with five 50% lethal doses (LD50s) of anthrax spores, were given
a single 16.7-mg/kg of body weight AVP-21D9 antibody dose combined with ciprofloxacin (30 mg/kg/day for 6
days) 24 h after challenge, 100% of the mice were protected for more than 30 days, while ciprofloxacin or
AVP-21D9 alone showed minimal protection. Similarly, when AVP-21D9 antibody (10 to 50 mg/kg) was
combined with a low, nonprotective dose of ciprofloxacin (3.7 mg/kg/day) and administered to guinea pigs for
6 days, synergistic protection against anthrax was observed. In contrast, a single dose of AVP-21D9 antibody
(1, 5, 10, or 20 mg/kg) but not 0.2 mg/kg alone completely protected rabbits against challenge with 100 LD50s
of B. anthracis Ames spores, and 100% of the rabbits survived rechallenge. Further, administration of AVP-
21D9 (10 mg/kg) to rabbits at 0, 6, and 12 h after challenge with anthrax spores resulted in 100% survival;
however, delay of antibody treatment by 24 and 48 h reduced survival to 80% and 60%, respectively. Serological
analysis of sera from various surviving animals 30 days postprimary infection showed development of a
species-specific PA enzyme-linked immunosorbent assay antibody titer that correlated with protection against
reinfection. Taken together, the effectiveness of human anti-PA antibody alone or in combination with low
ciprofloxacin levels may provide the basis for an improved strategy for prophylaxis or treatment following
inhalation anthrax infection.
The severest form of anthrax results from inhalation of
spores from Bacillus anthracis. The organism secretes three
protein toxin components encoded by the genes cya, lef, and
pag located on the pX01 plasmid (6, 20, 23). The virulence of
B. anthracis is in part attributed to two separate bacterial
proteins, edema factor (EF) (encoded by the cya gene) and
lethal factor (LF) (encoded by the lef gene), both of which
interact with protective antigen (PA) (encoded by the pag
gene), a third protein that binds to receptors (4, 16, 28, 30) on
the host cell surface, forming edema toxin and lethal toxin
(LeTx). EF, an 88.9-kDa protein, is a calmodulin-dependent
adenylyl cyclase enzyme, while the 90.2-kDa LF is a Zn2
metalloprotease (6, 23). The 82.7-kDa receptor-binding PA is
nicked by a furin-like protease produced by target cells and
heptamerizes, forming binding sites for EF and LF. The mem-
brane-bound holotoxin is then transported into the host cell by
receptor-mediated endocytosis. Acidification of the endosome
causes a conformational change in PA so that the protein
forms a channel in the endosomal membrane, thus facilitating
EF and LF entry into the cytosol, resulting in their respective
biological effects (6, 23).
PA possesses distinct antigenic epitopes that elicit neutral-
izing antibodies capable of protecting experimental animals
against inhalation anthrax (18). However, not all PA antibod-
ies are effective in neutralizing the toxin complex (22). In vivo
evaluation of protection provided by neutralizing anti-PA an-
tibodies can be performed in Fisher 344 rats injected with
LeTx. The monoclonal antibody AVP-21D9, derived from hu-
man blood lymphocytes from an anthrax vaccine adsorbed
(AVA)-immunized individual, has been shown to be highly
effective at LeTx neutralization (29). Protection against B.
anthracis infection, however, is a more complex and stringent
test of PA antibodies that block only the action of the anthrax
toxins, and the small-animal models of inhalation anthrax vary
in the extent to which anti-PA antibodies confer protection (9,
11, 19, 26, 27, 38). Nonhuman primates and rabbits are often
considered the best models because they can be most effec-
tively protected by the AVA vaccine, which contains PA and
* Corresponding author. Mailing address: Department of Microbi-
ology and Immunology, University of Texas Medical Branch, 301 Uni-
versity Blvd., Galveston, TX 77555-1070. Phone: (409) 772-4910. Fax:
(409) 772-4924. E-mail: johnny.peterson@utmb.edu.
† Present address: The School of Biosciences, University of West-
minster, London SW6 6AB, United Kingdom.
1016
other B. anthracis-derived components (11, 26, 27, 38). In con-
trast, guinea pigs and mice appear more difficult to protect with
the AVA vaccine (2, 9, 19).
In this study, we evaluated the capacity of a fully character-
ized human monoclonal anti-PA antibody (AVP-21D9), alone
and combined with limited ciprofloxacin doses, to protect mice
and guinea pigs against lethal doses of B. anthracis spores
administered by the intranasal route. Further, AVP-21D9 was
tested in rabbits for its protective capacity against intranasal
challenge. This potent human monoclonal anti-PA antibody
was reported to block PA heptamer formation and to neutral-
ize LeTx in vitro and in vivo in a rat toxin neutralization assay
(29, 35). In this report, we have demonstrated for the first time
that a single dose of AVP-21D9 could delay death in mice and
guinea pigs and completely protect rabbits, following lethal
challenge by nasal instillation of B. anthracis Ames spores. In
combination with low ciprofloxacin doses, AVP-21D9 could
significantly enhance and prolong the survival of both mice and
guinea pigs. Differences in the roles of the B. anthracis toxins
and the bacterial capsule in the three animal models are
thought to account for the variation in protection observed.
MATERIALS AND METHODS
B. anthracis toxin proteins. PA, LF, and EF were from the Biodefense and
Emerging Infections Research Resources Repository (BEI Resources, Manas-
sas, VA).
Human monoclonal antibody to PA. AVP-21D9 (Avanir Pharmaceuticals, San
Diego, CA) is a wholly human monoclonal antibody specific for PA and was
produced by CHO (Chinese hamster ovary)-K1 cells adapted to growth in serum-
free medium in Integra cell culture flasks or in a bioreactor by VaxGen, Inc.,
Brisbane, CA, for Avanir Pharmaceuticals (29, 35). The protein A-purified AVP-
21D9 antibodies showed a purity of 95% as judged by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis analysis, the binding affinity to PA was within
0.05  0.03 nM (n  8 different batches) as determined on the BiaCore 3000
instrument (Piscataway, NJ), and the 50% effective concentration in the Centers
for Disease Control and Prevention (CDC) standardized toxin neutralization
assay using the J774.1 macrophage cell line was previously reported to be 0.02
nM (n  25) (27a; C. P. Quinn [Centers for Disease Control and Prevention,
Atlanta, Ga., personal communication).
Preparation of B. anthracis spores. Spores were prepared by inoculating B.
anthracis Ames strain in 2 SG sporulation medium (pH 7.0) consisting of 16 g
Difco Nutrient Broth, 0.5 g MgSO4 · 7H2O, 2.0 g KCl, and 16.7 g MOPS
(morpholinepropanesulfonic acid) per liter (17). Before inoculation, the follow-
ing supplements were added to the medium after filter sterilization using
0.22-m syringe filters: 0.1% glucose, 1 mM Ca(NO3)2, 0.1 mM MnSO4, and 1
M FeSO4. Cultures were grown in 50-ml aliquots contained in 500-ml Erlen-
meyer flasks fitted with Bug Stoppers (Fisher Scientific, Hampton, NH) at 37°C
with gentle shaking (80 to 90 rpm) for 24 h, after which 100 ml of sterile distilled
water was added to dilute the medium and promote sporulation. After 10 to 11
days of continuous shaking, sporulation was confirmed at 99% via the mala-
chite green spore stain, and the spores were centrifuged at 587  g in a sealed-
carrier centrifuge (Jouan Inc., Winchester, VA) at 4°C for 15 min. The spore
pellets were then washed four times in sterile phosphate-buffered saline (PBS)
and resuspended in the same buffer. The spore suspensions were homogeneous
when examined by phase-contrast microscopy. Plate counts were performed in
triplicate to establish the concentration of viable spores in the suspension, which
was then adjusted to a concentration of 1  109 CFU/ml. Aliquots of the stock
spore suspension were stored at 70°C and freshly diluted in PBS to the desired
density of CFU immediately before each animal challenge experiment. B. an-
thracis cultures and spores were prepared and stored in a restricted-access bio-
safety level 2 laboratory registered with the CDC and inspected by the Depart-
ment of Defense and the United States Department of Agriculture.
Challenge of mice, guinea pigs, and rabbits with B. anthracis Ames spores. To
evaluate the protective efficacy of AVP-21D9 monoclonal antibody in vivo, we
challenged 8-week-old (25- to 30-g) female Swiss-Webster mice (Taconic, Ger-
mantown, NY) and 250- to 300-g Hartley guinea pigs (Charles River Laborato-
ries, Wilmington, MA) intranasally with 5  104 CFU and 6  105 CFU of B.
anthracis Ames spores, respectively. We determined that these doses constituted
five 50% lethal doses (LD50s) per species (data not shown). Dutch-belted rabbits
(0.7 to 1.1 kg; Myrtle’s Rabbitry, Inc., Thompson Station, TN) were challenged
using similar procedures with 100 LD50s (1  107 CFU) of nasally instilled B.
anthracis Ames spores (the LD50 was established in our laboratory).
Mice and guinea pigs were anesthetized by intraperitoneal (i.p.) injection with
a mixture of ketamine-HCl (48 mg/kg of body weight for mice and 30 mg/kg for
guinea pigs) and xylazine-HCl (9.6 mg/kg for mice and 7 mg/kg for guinea pigs).
The rabbits were anesthetized with ketamine (35 mg/kg) and xylazine (5 mg/kg)
by intramuscular injection. For spore instillation, anesthetized animals were sus-
pended vertically, using the upper incisors, as described by Comer et al. (7), with
the bulk of the body weight of the larger animals resting on the base of the
platform. The spore suspension was instilled slowly for 2 to 3 min onto the anterior
opening of each naris. Separate experiments instilling crystal violet dye solution
using this technique ensured that the inoculum was deposited in the trachea with
a minimal amount in the esophagus. The challenge volume was 20 l/naris for
mice, 25 l/naris for guinea pigs, and 50 l/naris for rabbits. PBS (20, 25, and 50
l/naris) was then used to wash any nonadherent spores from the nasal cavity
into the lungs for each animal species. All animal challenges were performed in
a select-agent-approved, restricted-access animal biosafety level 3 laboratory
under an approved Institutional Animal Care and Use Committee protocol.
Passive immunization and ciprofloxacin administration. Generally, 24 h after
intranasal challenge with B. anthracis Ames spores (a five-LD50 dose), mice were
passively immunized with a single subcutaneous (s.c.) dose of 500 g/mouse (16.7
mg/kg) of AVP-21D9, and some animals were also injected with ciprofloxacin
(0.9 mg/day; 30 mg/kg/day/mouse) by the i.p. route twice daily (b.i.d.) for 6 days.
The AVP-21D9 contained 20 mM Tris, 150 mM NaCl, and 0.01% Tween 80.
Guinea pigs were given a single i.p. injection of 3.1 mg (10 mg/kg), 6.2 mg (20
mg/kg), or 15 mg/guinea pig (50 mg/kg) of AVP-21D9, either 6 h prechallenge or
24 h postchallenge (as indicated) and s.c. injections of 1.12 (3.7 mg/kg/day), 2.25
(7.5 mg/kg/day), or 4.5 mg (15 mg/kg/day/guinea pig) of ciprofloxacin b.i.d. for 6
days starting 24 h after challenge with five LD50s of B. anthracis Ames spores.
Control groups of animals received AVP-21D9 antibody alone, ciprofloxacin
only, or no treatment. Rabbits were given a single s.c. injection of AVP-21D9
monoclonal antibody (0.2, 1, 5, 10, and 20 mg/kg) at the same time as nasal
challenge with 100 LD50s of B. anthracis Ames spores. In the delayed-treatment
experiment, rabbits were injected s.c. with AVP-21D9 (10 mg/kg) at various times
(0, 6, 12, 24, and 48 h) following intranasal challenge with B. anthracis spores.
Serological assay. Antibody capture enzyme-linked immunosorbent assays
(ELISA) for PA were used to determine the adaptive immune responses of mice,
guinea pigs, and rabbits to antigens from the B. anthracis Ames spore infection.
Briefly, blood samples were collected in serum separator microtubes containing
silicone (Becton Dickinson, Franklin Lakes, NJ) 30 days postchallenge, and the
sera were harvested by centrifugation at 519  g for 5 min. For the ELISA,
twofold serial dilutions of the sera were made beginning at 1:20 in 96-well
flat-bottom cell culture plates (Corning Inc., Acton, MA) coated with 5 g/ml PA
(BEI Resources) diluted in sodium carbonate buffer (pH 9.6). The plates were
then washed with PBS containing 0.05% Tween 20 and blocked for 1 h with PBS
containing 10% fetal bovine serum. After 1 h of incubation at room temperature,
the plates were washed three times with PBS plus 0.05% Tween 20, and mouse,
guinea pig, or rabbit anti-PA immunoglobulin G (IgG) was detected by adding
0.5 g/ml goat anti-mouse, anti-guinea pig, or anti-rabbit IgG, respectively,
conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz,
CA). The plates were developed with ABTS substrate [2,2-azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid] (Sigma Chemical Co., St. Louis, MO) for 20 to 60
min, and absorbance at 405 nm was measured with a BioTek Synergy HT
spectrofluorometer (Bio-Tek Instruments, Inc., Winooski, VT). The final an-
ti-PA titers were established by the dilution that yielded one-half of the maxi-
mum absorbance in the ELISA anti-PA control (optical density at 405 nm).
In vitro toxin neutralization assay. We measured lactate dehydrogenase
(LDH) enzyme release from a murine monocyte-macrophage cell line (RAW
264.7; American Type Culture Collection, Manassas, VA) to assess the protec-
tion afforded by sera from guinea pigs and rabbits that were challenged with B.
anthracis Ames spores. Briefly, the RAW 264.7 cells were propagated in Dul-
becco’s modified essential medium supplemented with 10% fetal bovine serum,
100 g/ml penicillin-streptomycin, and 2 mM L-glutamine (Mediatech, Inc.,
Herndon, VA) at 37°C with 5% CO2 using tissue culture flasks. Subsequently, the
cells were plated in 96-well flat-bottom tissue culture plates (Corning) at a
density of 1  106 cells/ml and incubated overnight at 37°C in 5% CO2. The
monolayers were washed twice with Dulbecco’s modified essential medium de-
void of serum or phenol red. LeTx-mediated cytotoxicity was measured as a
function of the amount of LDH enzyme released from the macrophages into the
cell culture supernatants. Various dilutions of the infected (for 30 days) guinea
pig and rabbit sera (starting from 1:10 dilution, followed by twofold serial dilu-
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tions) were preincubated with 12 nM PA (1.0 g/ml) and 2 nM LF (0.2 g/ml)
for 1 h at 37°C and added to the culture media. After incubation for 4 h, LDH
release in the supernatant of the macrophage cells was measured using the
CytoTox 96 nonradioactive cytotoxicity assay kit (Promega, Madison, WI) and
quantitated by measuring wavelength absorbance at 490 nm. The final neutral-
izing antibody titers of sera were reported as the reciprocal of the dilution that
resulted in 50% of the difference between the relative amounts of LDH release
in the untreated culture media and LeTx controls.
Pharmacokinetic studies. To determine the serum concentrations of AVP-
21D9 antibody in Swiss-Webster mice over time, a group of five 20-g mice each
received 1 mg (50 mg/kg) AVP-21D9 by i.p. injection, either as a bolus at time
zero or as two injections of 0.5 mg (25 mg/kg) each at time zero and 72 h later.
Serum samples were collected by retro-orbital bleeding at 1, 6, 12, 24, 48, 72, 73,
78, 84, 96, 120, 144, 168, 192, 216, and 240 h.
To assess the serum concentrations of AVP-21D9 antibody in Hartley guinea
pigs (250 to 300 g) over time, two groups of three guinea pigs each received a
single i.p. injection of 1.5 (5 mg/kg) or 15 mg (50 mg/kg) of the antibody. Blood
samples were collected by toenail bed snips at 0, 6, 12, 24, 48, 72, 168, and 216 h
after injection.
To determine the levels of AVP-21D9 in rabbits, four Dutch-belted rabbits
(1.3 to 1.7 kg) were injected with 1 and 10 mg/kg of the antibody by s.c. injection.
Blood samples were collected from the central ear artery with a 1-ml syringe
fitted with a 25-gauge needle.
The AVP-21D9 antibody concentrations in the sera were measured by surface
plasmon resonance using a Biacore 3000. Briefly, a goat anti-human IgG capture
antibody (Jackson Immuno Research Inc., West Grove, PA) was coupled to flow
cell number 1 of a CM-5 sensor chip (Biacore catalog no. BR-1003-99) at a level
of 10,000 response units using an Amine Coupling Kit (Biacore catalog no.
BR-1000-50). Human IgG1 (20 g/ml; Sigma I-5154) was used to generate a
standard curve. Antibody serum samples were diluted 1:10 and 1:100 in HBS-EP
buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Surfac-
tant P20). Each sample was assayed in duplicate, and standards were assayed in
triplicate. Response unit values were taken 2 min into the injection of the
standards and samples, and Biacore evaluation software was used to generate a
standard curve from which unknown sample concentrations were calculated.
RESULTS
Mouse protection experiments. Figure 1 summarizes an ex-
periment in which AVP-21D9 monoclonal antibody was tested
for its capacity to protect mice against lethal infection with B.
anthracis Ames spores (five LD50s) administered by nasal in-
stillation given alone and in combination with ciprofloxacin
24 h after challenge. Combinations of AVP-21D9 and antibi-
otic were examined, because treatment of human disease with
human anti-PA antibody would most likely occur in conjunc-
tion with approved antibiotics. Mice dosed i.p. with a single
16.7-mg/kg dose of AVP-21D9 antibody alone showed a min-
imal, statistically nonsignificant amount of protection com-
pared to animals that were challenged with anthrax spores
(PBS control). Our earlier experiments demonstrated that 30
mg/kg/day of ciprofloxacin (b.i.d.) for 6 days was a suboptimal
antibiotic dose for protecting mice against B. anthracis infec-
tion (data not shown). However, when we combined cipro-
floxacin treatment (30 mg/kg/day) and passive immunization
with a single 16.7-mg/kg dose of AVP-21D9 in anthrax spore-
challenged mice, 100% protection was achieved for 38 days,
suggesting at least an additive effect, because ciprofloxacin or
AVP-21D9 alone protected only 60% and 40% of the mice,
respectively. Upon rechallenge, only 5% of the mice survived,
indicating that long-term protection with the heterologous hu-
man monoclonal antibody was not achieved.
Guinea pig protection experiments. In testing AVP-21D9 in
guinea pigs, we determined the amount of protection afforded
by administration of 10 mg/kg, 20 mg/kg, and 50 mg/kg of
AVP-21D9 6 h before challenge with five LD50s (6 10
5 CFU)
of B. anthracis Ames spores by nasal instillation (Fig. 2). The
results indicated that increasing the dose to 50 mg/kg did not
significantly increase the protection observed. As is evident
from the figure, administration of anti-PA antibody to guinea
pigs delayed their deaths compared to animals infected with
the spores alone; however, most animals were still susceptible
to lethal infection.
To distinguish between additive effects and synergy by AVP-
21D9 and ciprofloxacin, we challenged guinea pigs intranasally
with Ames spores, and 24 h later administered AVP-21D9 (50
mg/kg i.p.) concomitantly with three different doses of cipro-
floxacin administered by the s.c. route twice daily for 6 days
(Fig. 3A to C). Figure 3A shows a synergistic, rather than an
additive, protective effect of combining a suboptimal dose of
ciprofloxacin (3.7 mg/kg/day) and AVP-21D9 (50 mg/kg). As
ciprofloxacin doses were increased to 7.5 mg/kg/day (Fig. 3B),
synergistic protection was reduced to the anticipated additive
effects of ciprofloxacin and AVP-21D9. When the ciprofloxacin
dose was increased still further to 15 mg/kg/day (Fig. 3C), the
protection by AVP-21D9 monoclonal antibody was obscured
by the protection afforded by the antibiotic alone. Another
experiment, shown in Fig. 4, confirmed the synergistic protec-
tion afforded to guinea pigs by low-dose ciprofloxacin (3.7
mg/kg/day) and low doses (5 mg/kg) of AVP-21D9 against
nasal instillation of anthrax spores. Analogous to results with
the mouse model, long-term survival of the guinea pigs after
injection of human monoclonal antibody was not observed
following secondary challenge.
Rabbit protection experiments. Protection of rabbits against
a lethal challenge of B. anthracis spores with AVP-21D9 was
FIG. 1. Protection of Swiss-Webster mice with combinations of
AVP-21D9 and a low nonprotective dose of ciprofloxacin after chal-
lenge with five LD50s of B. anthracis Ames. Human monoclonal anti-
body to PA (AVP-21D9) (16.7 mg/kg) was administered as a single s.c.
dose 24 h after challenge with B. anthracis Ames spores, while cipro-
floxacin (30 mg/kg/day) was administered by i.p. injection. The number
of animals per group was 10. The data were analyzed statistically using
the Fisher exact test, and a P value of0.05 was considered significant.
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easily demonstrated, thereby showing the human anti-PA an-
tibody to be highly effective (Fig. 5). Unlike the partial pro-
tection observed in the mouse and guinea pig models, AVP-
21D9 was 100% effective in protecting rabbits for 3 weeks
against 100 LD50s of B. anthracis spores administered intrana-
sally when given in doses of 1, 5, 10, and 20 mg/kg (Fig. 5). A
lower dose of AVP-21D9 (0.2 mg/kg) failed to protect the
rabbits from inhalation anthrax, with 80% of the animals dying
between 5 and 6 days after infection. In a subsequent delayed-
treatment experiment, administration of AVP-21D9 (10 mg/
kg) to rabbits at 0, 6, and 12 h after challenge with 100 LD50s
of B. anthracis Ames spores resulted in 100% survival for 30
days, compared to controls (0% survival). Delay of AVP-21D9
treatment by 24 h and 48 h reduced survival to 80% and 60%,
respectively (Fig. 6). For the most part, these animals were
protected when subsequently rechallenged with another 100
LD50s of anthrax spores. When all three animal models of
inhalation anthrax were compared, it became clear that rabbits
were more easily protected by anti-PA antibody than mice or
guinea pigs.
Serological analysis of infected animals. Passive administra-
tion of AVP-21D9 conferred protection against inhalation an-
thrax, although in mice and guinea pigs, concomitant admin-
istration of ciprofloxacin was necessary to demonstrate the
additive/synergistic protective response. To evaluate the role of
the adaptive immune response in mice to PA following nasal
rechallenge, we evaluated the sera of mice surviving challenge
with five LD50s of B. anthracis Ames spores for 30 days post-
primary challenge by murine-specific PA ELISA. The results
revealed that most of the mice (18/21) dosed with AVP-21D9
and/or ciprofloxacin failed to build a murine anti-PA antibody
response (
1:20) post-primary challenge, and all but one died
following nasal rechallenge (data not shown).
We measured low levels of residual human IgG antibody
specific for PA (AVP-21D9) by species-specific PA ELISA in
sera from 22 guinea pigs surviving 30 days post-primary chal-
lenge (geometric mean titer, 1:41, or 40-ng/ml AVP-21D9
equivalents). This residual human anti-PA antibody could have
provided some protection to the guinea pigs upon rechallenge;
however, we also sought to examine the animals’ adaptive
immune response to PA post-primary challenge. Serum sam-
ples were collected from the guinea pigs surviving 30 days (Fig.
3 and 4) post-primary challenge with five LD50s of B. anthracis
spores. In our analysis, guinea pig-specific anti-PA ELISA se-
rum titers and LeTx neutralization titers, illustrated in Fig. 7A
and B, from two experiments (Fig. 3 and 4) were combined. Of
the guinea pigs that survived secondary challenge, 41.7% (15/
36) had developed species-specific anti-PA ELISA titers of
1:300, with a geometric mean titer of 1:3,860 (range, 1:300 to
1:40,000) by 4 weeks post-primary challenge (Fig. 7A). Fur-
ther, 89.5% (17/20) of the guinea pigs that died after secondary
challenge had no detectable species-specific anti-PA ELISA
titer (1:20). One animal with a species-specific anti-PA
ELISA titer of 1:160 and another with a titer of 1:5,000 did not
survive rechallenge, and one animal with a titer of 1:20 sur-
vived the secondary challenge. Despite these exceptions, the
results (Fig. 7A) indicated a strong relationship between sur-
vival after rechallenge and an animal’s capacity to develop an
anti-PA antibody response following initial spore challenge.
These results were supported by additional titration of the sera
by an LeTx neutralization assay in RAW 264.7 cells (Fig. 7B),
although the neutralization titers were low and the difference
in titers between the two groups of guinea pigs (those that
survived [1:47] versus those that did not survive [1:11]) was not
as prominent.
Sera from rabbits surviving 3 weeks after primary challenge
with 100 LD50s (1  10
7 CFU) of B. anthracis Ames spores by
nasal instillation (Fig. 5) were assayed for residual human
anti-PA antibody titers (AVP-21D9) by a species-specific PA
ELISA. The geometric means of human anti-PA ELISA titers
from sera from rabbits dosed 3 weeks earlier with 5, 10, or 20
mg/kg of AVP-21D9 were 1:118, 1:373, and 1:691, which cor-
responded to 118-, 373-, and 691-ng/ml AVP-21D9 equiva-
lents, respectively. LeTx neutralization titers of sera from rab-
bits dosed with 10 and 20 mg/kg of AVP-21D9 were 1:51 and
1:106, respectively. All rabbits dosed with 1, 5, 10, and 20
mg/kg of AVP-21D9 survived rechallenge and were euthanized
2 weeks later.
The same sera from rabbits surviving 3 weeks after primary
challenge were also assayed for newly formed rabbit anti-PA
antibodies by species-specific PA ELISA. We observed that the
rabbits dosed with 20 mg/kg of AVP-21D9 3 weeks earlier built
species-specific geometric mean anti-PA titers of 1:146 (n 7),
while rabbits that had been dosed with 10 mg/kg of AVP-21D9
had formed rabbit anti-PA titers of 1:80 (n  6). Rabbits
receiving lower doses of AVP-21D9, specifically 5 or 1 mg/kg,
had titers of 1:288 (n  7) and 1:260 (n  7), respectively. The
human IgG (AVP-21D9 control) in these assays did not cross-
react with the goat anti-rabbit IgG conjugate used in the
ELISA (data not shown).
Finally, we examined sera from mice, guinea pigs, and rab-
FIG. 2. Protection of Hartley guinea pigs with human monoclonal
	-PA antibody (AVP-21D9). The figure shows the protective effects of
10 mg/kg, 20 mg/kg, and 50 mg/kg of AVP-21D9. The numbers of
animals per group were as follows: PBS control, n  16; 50-mg/kg PA
antibody group, n  10; 10- and 20-mg/kg PA antibody groups, n  6.
The data were analyzed statistically using the Fisher exact test, and a
P value of 0.05 was considered significant.
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bits for development of species-specific antibodies to the for-
eign human monoclonal antibody AVP-21D9. As expected, all
animals passively immunized with AVP-21D9 generated serum
anti-AVP-21D9 ELISA titers (data not shown). The immune
response to AVP-21D9 could have hastened clearance of the
foreign human antibody from the circulation prior to second-
ary challenge and/or contributed to neutralization of AVP-21D9.
Pharmacokinetic studies of AVP-21D9 antibody. Pharmaco-
kinetic parameters were obtained in mice, guinea pigs, and
rabbits (Table 1). An initial experiment with mice showed a
maximum concentration of antibody in serum (Cmax) of 692 
155 g/ml that was reached after 5  2 h following a bolus i.p.
injection of 50 mg/kg AVP-21D9. The antibody was rapidly
eliminated, with an elimination half-life of 2.8  1.4 days.
Administration of two doses of 25 mg/kg yielded superimpos-
able terminal elimination curves (data not shown). Similar
serum levels (Cmax  585 g/ml) were observed in guinea pigs
injected i.p. with 50 mg/kg of AVP-21D9. The time to maxi-
FIG. 3. Protection of Hartley guinea pigs with combinations of AVP-21D9 (50 mg/kg) and various doses of ciprofloxacin: (A) 3.7 mg/kg/6 days;
(B) 7.5 mg/kg/6 days; (C) 15 mg/kg/6 days. The number of animals per group was five. The data were analyzed statistically using the Fisher exact
test, and a P value of 0.05 was considered significant.
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mum concentration of antibody in serum was reached later (28
 14 h), and the elimination half-life was longer (13.8  8.1
days), but there was a lot of variability in this group (the
elimination half-lives were 5.4, 14.5, and 21.5 days versus 2.5,
5.2, and 5.7 days in the 5-mg/kg group). The Cmax, as well as the
total amount of AVP-21D9 detected in the serum over the
time course of the study (area under the curve [AUC] from
time zero to the last measured time point) was reduced ap-
proximately 10-fold in guinea pigs given 5 mg/kg AVP-21D9
compared to those that received 50 mg/kg, indicating a linear
dose response at these dosing levels (Table 1). An additional
study was performed in Dutch-belted rabbits, which were given
a single s.c. dose of AVP-21D9 at 1 mg/kg or 10 mg/kg, and
serum samples were collected for 14 days. The s.c. route was
chosen to eliminate unwanted potential variability of i.p. dos-
ing and to more closely mimic a potential route for human
administration. At the 1-mg/kg dose, which completely pro-
tected the rabbits from anthrax spore challenge, we observed a
Cmax of 23 g/ml that was reached after 2 days. Moreover,
administration of 10 mg/kg AVP-21D9 yielded approximately
10-fold-higher Cmax and corresponding AUC values, confirm-
ing the dose proportionality seen earlier in guinea pigs. The
terminal elimination half-life is comparable to that in guinea
pigs (5 to 9 days) and much lower than would be expected for
a fully human antibody administered to humans.
DISCUSSION
The pathology of inhalation anthrax in humans and animal
models is well characterized and was discussed in prior reports
(11, 13, 19, 27, 34, 38). It is clear that B. anthracis strains
possessing both plasmids pX01 and pX02 are fully virulent in
small-animal models, such as the mouse, guinea pig, and rab-
bit, and that deletion of either or both plasmids reduces viru-
lence (5, 9, 25). It is generally believed that anthrax toxins play
a more important role in virulence in humans, nonhuman
primates, and rabbits than in mice and guinea pigs during
inhalation anthrax (11, 26, 27, 38). The reasons for these dif-
ferences in the animal models are not known. Despite incon-
sistencies in the anthrax animal models, each offers advantages
for examining new strategies in vaccination and therapy to
protect against the disease. In general, therapeutic and pro-
phylactic approaches that prove effective against inhalation
anthrax in the mouse and guinea pig models are likely to be
highly effective in rabbits and nonhuman primates.
Since B. anthracis spores germinate asynchronously and of-
ten cause infection long after exposure, a prolonged period of
prophylactic treatment with antibiotics is required (2, 10, 12,
33). Because treatment regimens are lengthy, we investigated
the protective effect of the human monoclonal antibody AVP-
21D9, specific for B. anthracis PA, alone and in combination
with ciprofloxacin using mouse, guinea pig, and rabbit models
of intranasal challenge.
Currently, there are several anti-PA monoclonal antibodies
at various stages of development (14, 15, 21, 32, 37), but a
direct comparison of the potencies of these antibodies in the
same animal model is lacking. Two reports described antibod-
ies that neutralize LeTx in a toxin challenge model (14, 37), but
data from a spore challenge model have not yet been reported.
Another group showed protection of A/J mice challenged with
30 LD50s of B. anthracis Sterne strain spores by 180 g of a
plant-derived version of anti-PA antibodies obtained from
IQ6E4 hybridomas (IQ Corporation, The Netherlands) admin-
istered 2.5 h before challenge (15). More comparable to the
studies described in this report, Beebe et al. (3) reported 100%
FIG. 4. Protection of Hartley guinea pigs treated with low-dose
ciprofloxacin (3.7 mg/kg for 6 days) in combination with a single i.p.
dose of AVP-21D9 (5 mg/kg) administered 24 h after challenge. The
number of animals per group was nine. The data were analyzed sta-
tistically using the Fisher exact test, and a P value of 0.05 was
considered significant.
FIG. 5. Survival of Dutch-belted rabbits after challenge intranasally
with 100 LD50s (1  10
7 CFU) of B. anthracis Ames spores with and
without concomitant dosing with 0.2, 1, 5, 10, and 20 mg/kg of AVP-
21D9 by the subcutaneous route. The numbers of animals per group
were 11 for the PBS control, 6 for the 0.2-mg/kg group, and 7 for the
1-, 5-, 10-, and 20-mg/kg groups. The data were analyzed statistically
using the Fisher exact test, and a P value of 0.05 was considered
significant.
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protection of New Zealand White (NZW) rabbits challenged
by the aerosol route with 100 LD50s of Ames spores when 40
mg/kg of human PA monoclonal antibody (5H3; ABthrax) was
administered intravenously at the time of challenge. Cui et al.
showed that a PA monoclonal antibody significantly improved
the outcome of a lethal toxin infusion rat model when the
antibody was administered at 10-fold molar excess to PA up to
6 h after initial exposure to LeTx (8). This human antibody was
found to be safe and well tolerated when administered as a
single intramuscular or intravenous dose in a human phase I
trial at doses ranging from 0.3 to 40 mg/kg (32).
Similar results were reported for ETI-204, a chimeric an-
ti-PA antibody with an equilibrium dissociation constant of
0.33 nM, which provided 90 to 100% protection when given at
10 mg/kg to NZW rabbits prior to challenge with 100 to 200
LD50s of aerosolized B. anthracis Ames spores (21). As shown
in this report, AVP-21D9 provided full protection to rabbits at
1 mg/kg (i.e., a 40-fold-lower dose than the above-mentioned
PA monoclonal antibody 5H3), and it provided complete pro-
tection to rabbits even when administered subcutaneously 12 h
post-spore challenge, with peak levels of serum antibody being
reached 40 h later. A potency similar to that of AVP-21D9, i.e.,
protection at 1 mg/kg, has been claimed only for MDX-1303
(Valortim), but the data have not been published other than in
a press release and therefore could not be independently con-
firmed. We anticipate that AVP-21D9 will have a safety profile
in humans similar to those of the above-mentioned PA mono-
clonal antibodies and will potentially require lower doses of
antibody, which are expected to be achievable by various
routes of administration in humans. These qualities should
qualify AVP-21D9 as a top candidate for further development
for use in humans, either for preexposure/postexposure pro-
phylaxis or for therapeutic treatment of individuals exposed to
anthrax spores.
The affinity measurements from eight different lots of AVP-
21D9 antibody showed an average equilibrium dissociation
constant of 0.05  0.03 nM. Further characterization of the
antibody determined that it inhibited PA heptamer formation,
a prerequisite for toxin entry into the cell (35). In this report,
the pharmacokinetic results in uninfected mice, guinea pigs,
and rabbits revealed the presence of peak levels of AVP-21D9
antibody in blood during the critical period (2 to 5 days) when
deaths from inhalation anthrax occurred with the highest fre-
quency (Table 1). The elimination half-life and serum levels in
Dutch-belted rabbits reported here are comparable to the val-
ues reported for other anti-PA antibodies in NZW rabbits (3,
18), and it is expected that the half-life of the fully human
AVP-21D9 will be significantly increased in humans (32). How-
FIG. 6. Survival of Dutch-belted rabbits after challenge intranasally
with 100 LD50s (1  10
7 CFU) of B. anthracis Ames spores and dosing
with 10 mg/kg AVP-21D9 by the subcutaneous route at 0, 6, 12, 24, and
48 h postchallenge. The number of animals per group was five. The
data were analyzed statistically using the Fisher exact test, and a P
value of 0.05 was considered significant.
FIG. 7. Correlation of guinea pig anti-PA titers with survival fol-
lowing rechallenge with B. anthracis Ames spores. Blood samples from
guinea pigs surviving initial challenge were collected at 30 days, and
their sera were analyzed by guinea pig-specific ELISA for anti-PA
(A) or -LeTx (B) neutralization assay in RAW 264.7 cells.
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ever, the serum levels alone are not predictive of protection in
all of the animal models. For example, the Cmax of AVP-21D9
in Dutch-belted rabbits was only 23  3 g/ml in the fully
protected group treated with 1 mg/kg AVP-21D9, while guinea
pigs treated with 50 mg/kg AVP-21D9 reached a Cmax of 580
16 g/ml but were not fully protected by antibody alone.
We observed that AVP-21D9 anti-PA alone delayed the
deaths of mice and guinea pigs from anthrax and, when com-
bined with low doses of ciprofloxacin, conferred additive or
synergistic protection in both of the models. We surmised that
the lower levels of antibiotic allowed some replication of the
bacteria, which in turn served as a potent source of PA and
other antigens that elicited an adaptive immune response. The
synergy observed between ciprofloxacin and the human an-
ti-PA antibody offers promise for future improvements in pro-
phylaxis and treatment against inhalation anthrax.
We determined that mice, guinea pigs, and rabbits formed a
specific antibody response to AVP-21D9 (human IgG). We do
not anticipate that this will occur in humans dosed with AVP-
21D9, since it is a wholly human monoclonal antibody. Passive
immunization with human monoclonal antibodies to PA offers
an opportunity to protect or treat patients exposed to B. an-
thracis spores. It is unlikely that unvaccinated patients at risk of
contracting anthrax would be treated using an effective anti-
body alone, simply because of the gravity of the infection, the
fulminating course of the clinical disease, the dangerously high
mortality of the infection for the affected patient, and ethical
issues related to the use of effective antibiotics. Consequently,
evaluation of new treatment regimens in combination with
antibiotics is a rational medical practice. Fortunately, human-
to-human secondary transmission of inhalation anthrax has not
been reported (36).
We observed that AVP-21D9, with or without ciprofloxacin,
did not provide long-term protection to mice. Likewise, few
mice developed a species-specific anti-PA response, but it is
unclear whether this observation is related to the limited du-
ration of resistance. In contrast, we observed that if guinea pigs
were kept alive for 36 days, with ciprofloxacin and/or human
monoclonal antibody to PA following initial challenge with B.
anthracis spores, 50% (18/36) of them developed a geometric
mean guinea pig-specific anti-PA ELISA titer of1:300, which
provided them with an 80% chance of surviving rechallenge.
That one-half of the animals failed to develop an anti-PA
antibody response could have been due to the inhibitory effect
of the anthrax toxins on T cells formed during the primary
infection (1, 31). Exceptions to this generalization were three
dead animals that had anti-PA ELISA titers greater than 1:160
and the one survivor of rechallenge with an undetectable PA
antibody response. The low LeTx neutralizing antibody titers
possibly reflect a low survival rate after rechallenge. Based on
study results, we could have predicted with reasonable accu-
racy survival following rechallenge, based on a minimum an-
ti-PA ELISA titer of 1:300 (80% survival), but would have
been unable to predict survivors based on the low neutraliza-
tion titers, as neutralization titers of 1:30 yielded only a 50%
probability of an animal surviving rechallenge. These findings
do not imply that neutralization titers are unimportant in eval-
uating vaccines against anthrax, as the development of sero-
logical responses to PA, following experimental infection, was
likely reduced by the immunosuppressive effects of LeTx on
dendritic cells and lymphocytes (1, 24, 31).
Analysis of rabbit sera 3 weeks after dosing with AVP-21D9
and challenge with 100 LD50s of B. anthracis spores revealed
significant levels of AVP-21D9 remaining, which likely contrib-
uted to their protection against secondary challenge. These
animals were also protected by rising titers of rabbit anti-PA
antibody formed in response to PA and possibly other antigens
presented following initial challenge. Taken together, these
data indicated that development of anti-PA, and possibly an-
tibodies to other B. anthracis antigens, by the host immune
response was primarily responsible for providing protection to
the animals after subsequent challenge with B. anthracis spores.
In conclusion, protection of both guinea pigs and mice was
significantly enhanced by concomitant treatment with cipro-
floxacin and a potent human monoclonal antibody to PA
(AVP-21D9), but there were substantial differences in the two
models, with the mouse being the most difficult to protect with
antibodies to PA alone. In rabbits, AVP-21D9 alone was highly
effective in protecting against lethal infection. The importance
and strength of this study are that we evaluated the efficacy of
anti-PA monoclonal antibody in three small-animal models.
Our data support the further evaluation of AVP-21D9 in non-
human primate challenge models and in humans for safety as
a potential candidate for use in protecting humans exposed to
anthrax spores.
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